Get the Stockscreener App
1.17
1.68%
-0.02
After Hours:
1.18
0.01
+0.85%
Maxcyte Inc stock is traded at $1.17, with a volume of 415.92K.
It is down -1.68% in the last 24 hours and down -13.33% over the past month.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
See More
Previous Close:
$1.19
Open:
$1.2
24h Volume:
415.92K
Relative Volume:
0.42
Market Cap:
$120.75M
Revenue:
$32.29M
Net Income/Loss:
$-39.12M
P/E Ratio:
-3.1889
EPS:
-0.3669
Net Cash Flow:
$-29.51M
1W Performance:
-1.68%
1M Performance:
-13.33%
6M Performance:
+69.66%
1Y Performance:
-23.53%
1-Day Range:
$1.16
$1.20
1-Week Range:
$1.16
$1.25
52-Week Range:
$0.6434
$1.865
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.17 | 120.75M | 32.29M | -39.12M | -29.51M | -0.3669 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
MaxCyte names Sidharth Kapileshwar as CCDO - Medical Buyer
MaxCyte stock slips 4.03 percent as new chief arrives - AD HOC NEWS
MaxCyte appoints Sidharth Kapileshwar as chief corporate officer By Investing.com - Investing.com Australia
MaxCyte Names Sidharth Kapileshwar Chief Corporate Development Officer - citybiz
MaxCyte appoints Sidharth Kapileshwar as chief corporate officer - Investing.com
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer - manilatimes.net
MaxCyte's new executive has held strategy, innovation and M&A roles over nearly 25 years. - Stock Titan
MaxCyte stock falls as revenue and market value remain under pressure - AD HOC NEWS
MaxCyte stock edges higher as analysts stick to Strong Buy rating - AD HOC NEWS
MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
MaxCyte Inc (NASDAQ: MXCT) Stock Price, News & Analysis - Kalkine
MXCT stock holds steady as MaxCyte focuses on cell-therapy growth - ad-hoc-news.de
MXCT stock holds steady as MaxCyte prepares next growth steps - ad-hoc-news.de
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 2.42%Share Dilution Risk - vinanet.vn
MaxCyte Inc. (MXCT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
MaxCyte Inc. (MXCT) Peer Comparison – Compare with Others - valueresearchonline.com
MaxCyte stock rating held at Neutral by BTIG after Q2 results - Investing.com India
MaxCyte (MXCT) Q2 2026 Earnings: EPS Comes in Above Forecast in the Latest Reading; Market Reaction - vinanet.vn
MaxCyte Gets A Genentech Nod, But Revenue Still Comes In Chunks - Finimize
MaxCyte launches base editor off-target nomination assays By Investing.com - Investing.com Nigeria
MaxCyte (MXCT) Earnings Reading: EPS Prints Above Forecast in the Latest Session; Stock Move - vinanet.vn
MaxCyte launches base editor off-target nomination assays - Investing.com
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies - The Manila Times
MaxCyte launches a gene-editing test that sees population-specific DNA variants - Stock Titan
MaxCyte, Inc. Revenue Breakdown – NASDAQ:MXCT - TradingView
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript - The Globe and Mail
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Marks a 15.97% EPS Beat, Yet Shares Slip 5.04%Earnings Sentiment Score - vinanet.vn
Teleconferência de Resultados do 2T26 da MaxCyte (MXCT): Guidance Reafirmado com a Expansão da Parceria com a Genentech - TradingKey
Conferencia de resultados del T2 de 2026 de MaxCyte (MXCT): Se reafirman las proyecciones a medida que se amplía la alianza con Genentech - TradingKey
MaxCyte, Inc. Releases Q2 2026 Results: Cell Engineering Platform Momentum in FocusRevenue Inflection Point - dars.gov.et
MaxCyte (MXCT) Earnings Call Q2 2026: Prognose bekräftigt bei Ausbau der Genentech-Partnerschaft - TradingKey
MaxCyte (MXCT) Q2 2026 Earnings Call: Guidance Reaffirmed as Genentech Partnership Expands - TradingKey
Stifel Nicolaus Keeps Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
MaxCyte revenue down 15% to USD 7.3M in Q2 2026 - medicalbuyer.co.in
MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC - MarketBeat
Price to sales forward of MaxCyte, Inc. – MUN:MYE0 - TradingView
MaxCyte Reports Second Quarter 2026 Financial Results - manilatimes.net
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ... - Yahoo! Finance Canada
MXCT Looks 49.6% Undervalued on GF Value™ - GuruFocus
MaxCyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MaxCyte Q2 Earnings Call Highlights - MarketBeat
MaxCyte (NASDAQ:MXCT) Issues Earnings Results - MarketBeat
MaxCyte affirms FY26 sales guidance of $30M-$32M vs estimate - scanx.trade
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall - Investing.com
MaxCyte Reports Q2 Results, Highlights Genentech Partnership - TipRanks
MaxCyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):